Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Oncogene ; 32(31): 3616-26, 2013 Aug 01.
Article in English | MEDLINE | ID: mdl-22907436

ABSTRACT

Embryonal cancer can arise from postnatally persistent embryonal remnant or rest cells, which are uniquely characterized by the absence of p53 mutations. Perinatal overexpression of the MycN oncoprotein in embryonal cancer precursor cells causes postnatal rests, and later tumor formation through unknown mechanisms. However, overexpression of Myc in adult tissues normally activates apoptosis and/or senescence signals as an organismal defense mechanism against cancer. Here, we show that perinatal neuroblastoma precursor cells exhibited a transiently diminished p53 response to MycN oncoprotein stress and resistance to trophic factor withdrawal, compared with their adult counterpart cells from the TH-MYCN(+/+) transgenic mouse model of neuroblastoma. The adult stem cell maintenance factor and Polycomb group protein, Bmi1 (B-cell-specific Moloney murine leukemia virus integration site), had a critical role at neuroblastoma initiation in the model, by repressing p53 responses in precursor cells. We further show in neuroblastoma tumor cells that Bmi1 could directly bind p53 in a complex with other Polycomb complex proteins, Ring1A or Ring1B, leading to increased p53 ubiquitination and degradation. Repressed p53 signal responses were also seen in precursor cells for other embryonal cancer types, medulloblastoma and acute lymphoblastic leukemia. Collectively, these date indicate a general mechanism for p53 inactivation in some embryonal cell types and consequent susceptibility to MycN oncogenesis at the point of embryonal tumor initiation.


Subject(s)
Neoplasms, Germ Cell and Embryonal/pathology , Neoplastic Stem Cells/pathology , Nuclear Proteins/metabolism , Oncogene Proteins/metabolism , Polycomb Repressive Complex 1/metabolism , Proto-Oncogene Proteins/metabolism , Stress, Physiological , Tumor Suppressor Protein p53/chemistry , Tumor Suppressor Protein p53/metabolism , Animals , Apoptosis , Cell Line, Tumor , Cyclin-Dependent Kinase Inhibitor p16/metabolism , Humans , Leukemia/metabolism , Leukemia/pathology , Medulloblastoma/metabolism , Medulloblastoma/pathology , Mice , N-Myc Proto-Oncogene Protein , Neoplasms, Germ Cell and Embryonal/metabolism , Neoplastic Stem Cells/metabolism , Neuroblastoma/metabolism , Neuroblastoma/pathology , Polyubiquitin/metabolism , Proteasome Endopeptidase Complex/metabolism , Protein Stability , Proteolysis , Proto-Oncogene Proteins c-mdm2/metabolism , Signal Transduction , Ubiquitination
2.
Cell Death Differ ; 20(3): 503-14, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23175188

ABSTRACT

Myc oncoproteins are commonly upregulated in human cancers of different organ origins, stabilized by Aurora A, degraded through ubiquitin-proteasome pathway-mediated proteolysis, and exert oncogenic effects by modulating gene and protein expression. Histone deacetylases are emerging as targets for cancer therapy. Here we demonstrated that the class III histone deacetylase SIRT2 was upregulated by N-Myc in neuroblastoma cells and by c-Myc in pancreatic cancer cells, and that SIRT2 enhanced N-Myc and c-Myc protein stability and promoted cancer cell proliferation. Affymetrix gene array studies revealed that the gene most significantly repressed by SIRT2 was the ubiquitin-protein ligase NEDD4. Consistent with this finding, SIRT2 repressed NEDD4 gene expression by directly binding to the NEDD4 gene core promoter and deacetylating histone H4 lysine 16. Importantly, NEDD4 directly bound to Myc oncoproteins and targeted Myc oncoproteins for ubiquitination and degradation, and small-molecule SIRT2 inhibitors reactivated NEDD4 gene expression, reduced N-Myc and c-Myc protein expression, and suppressed neuroblastoma and pancreatic cancer cell proliferation. Additionally, SIRT2 upregulated and small-molecule SIRT2 inhibitors decreased Aurora A expression. Our data reveal a novel pathway critical for Myc oncoprotein stability, and provide important evidences for potential application of SIRT2 inhibitors for the prevention and therapy of Myc-induced malignancies.


Subject(s)
Proto-Oncogene Proteins c-myc/metabolism , Sirtuin 2/metabolism , Aurora Kinases , Cell Line, Tumor , Cell Proliferation , Endosomal Sorting Complexes Required for Transport , Gene Expression , Humans , Naphthols/pharmacology , Nedd4 Ubiquitin Protein Ligases , Phenylpropionates/pharmacology , Phosphorylation , Protein Binding , Protein Serine-Threonine Kinases/genetics , Protein Serine-Threonine Kinases/metabolism , Protein Stability , Proto-Oncogene Proteins c-myc/antagonists & inhibitors , Proto-Oncogene Proteins c-myc/genetics , RNA Interference , RNA, Messenger/metabolism , RNA, Small Interfering/metabolism , Sirtuin 2/antagonists & inhibitors , Sirtuin 2/genetics , Ubiquitin-Protein Ligases , Ubiquitination , Up-Regulation/drug effects
3.
Curr Cancer Drug Targets ; 11(7): 826-36, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21762080

ABSTRACT

Following the discovery that defective retinoid signaling directly contributes to tumorigenesis, and, that retinoids have an anti-cancer effect in vitro and in vivo, retinoids have become part of the routine care in children with neuroblastoma at the stage of minimal residual disease. However, many patients still relapse following retinoid therapy, demonstrating the need for more effective retinoids and better assays to predict retinoid sensitivity in cancer cells. Recent evidence suggests that the copper metabolism gene, ATP7A, is retinoid-regulated and an important component of the retinoic acid receptor ß (RARß) anticancer effect in neuroblastoma cells. To highlight and further develop the concept of using ATP7A as a target in retinoid therapy, and combination therapy with copper chelators in neuroblastoma, the current literature and abstracts related to the clinical application of retinoids, the function of ATP7A and the clinical application of copper chelators are summarized. We propose that strategies targeting the copper export protein, ATP7A, in combination therapy with retinoids and copper depletion therapy, may have great therapeutic potential in the clinical treatment of neuroblastoma and other malignancies.


Subject(s)
Adenosine Triphosphatases/metabolism , Cation Transport Proteins/metabolism , Neuroblastoma/drug therapy , Retinoids/therapeutic use , Adenosine Triphosphatases/antagonists & inhibitors , Cation Transport Proteins/antagonists & inhibitors , Copper-Transporting ATPases , Humans
4.
Oncogene ; 29(46): 6172-83, 2010 Nov 18.
Article in English | MEDLINE | ID: mdl-20729920

ABSTRACT

The family of tripartite-motif (TRIM) proteins are involved in diverse cellular processes, but are often characterized by critical protein-protein interactions necessary for their function. TRIM16 is induced in different cancer types, when the cancer cell is forced to proceed down a differentiation pathway. We have identified TRIM16 as a DNA-binding protein with histone acetylase activity, which is required for the retinoic acid receptor ß(2) transcriptional response in retinoid-treated cancer cells. In this study, we show that overexpressed TRIM16 reduced neuroblastoma cell growth, enhanced retinoid-induced differentiation and reduced tumourigenicity in vivo. TRIM16 was only expressed in the differentiated ganglion cell component of primary human neuroblastoma tumour tissues. TRIM16 bound directly to cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells. TRIM16 reduced cell motility and this required downregulation of vimentin. Retinoid treatment and enforced overexpression caused TRIM16 to translocate to the nucleus, and bind to and downregulate nuclear E2F1, required for cell replication. This study, for the first time, demonstrates that TRIM16 acts as a tumour suppressor, affecting neuritic differentiation, cell migration and replication through interactions with cytoplasmic vimentin and nuclear E2F1 in neuroblastoma cells.


Subject(s)
DNA-Binding Proteins/physiology , E2F1 Transcription Factor/antagonists & inhibitors , Neuroblastoma/pathology , Transcription Factors/physiology , Tumor Suppressor Proteins/physiology , Vimentin/antagonists & inhibitors , Animals , Cell Differentiation , Cell Movement , Cell Nucleus/metabolism , Cytoplasm/metabolism , E2F1 Transcription Factor/metabolism , Female , Humans , Mice , Mice, Inbred BALB C , Tripartite Motif Proteins , Ubiquitin-Protein Ligases , Vimentin/physiology
5.
Br J Cancer ; 100(1): 96-105, 2009 Jan 13.
Article in English | MEDLINE | ID: mdl-19127267

ABSTRACT

Increased retinoic acid receptor beta (RARbeta(2)) gene expression is a hallmark of cancer cell responsiveness to retinoid anticancer effects. Moreover, low basal or induced RARbeta(2) expression is a common feature of many human cancers, suggesting that RARbeta(2) may act as a tumour suppressor gene in the absence of supplemented retinoid. We have previously shown that low RARbeta(2) expression is a feature of advanced neuroblastoma. Here, we demonstrate that the ABC domain of the RARbeta(2) protein alone was sufficient for the growth inhibitory effects of RARbeta(2) on neuroblastoma cells. ATP7A, the copper efflux pump, is a retinoid-responsive gene, was upregulated by ectopic overexpression of RARbeta(2). The ectopic overexpression of the RARbeta(2) ABC domain was sufficient to induce ATP7A expression, whereas, RARbeta(2) siRNA blocked the induction of ATP7A expression in retinoid-treated neuroblastoma cells. Forced downregulation of ATP7A reduced copper efflux and increased viability of retinoid-treated neuroblastoma cells. Copper supplementation enhanced cell growth and reduced retinoid-responsiveness, whereas copper chelation reduced the viability and proliferative capacity. Taken together, our data demonstrates ATP7A expression is regulated by retinoic acid receptor beta and it has effects on intracellular copper levels, revealing a link between the anticancer action of retinoids and copper metabolism.


Subject(s)
Adenosine Triphosphatases/physiology , Cation Transport Proteins/physiology , Neuroblastoma/drug therapy , Receptors, Retinoic Acid/physiology , Adenosine Triphosphatases/genetics , Cation Transport Proteins/genetics , Cell Line, Tumor , Cell Proliferation , Copper/metabolism , Copper-Transporting ATPases , Gene Expression Regulation, Neoplastic , Humans , Neuroblastoma/pathology , Retinoids/pharmacology , Retinoids/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...